Several studies of IL-12 immunotherapies have shown encouraging results in animal models, but in humans they have been associated with only modest anti-tumour effects and a range of dose-limiting ...

During her show on Friday, the conservative podcast host said she wasn’t surprised that the new pope had disapproved of ...

Early findings from the SPARTAN phase II trial, presented at the National Kidney Foundation (NKF) Spring Clinical Meeting, ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and ...

Far from being a target during the first Trump administration, Chicago Women in Trades received two grants in 2019 and 2020 ...

“IL-23 inhibition is a novel mechanism of action compared with anti-integrin or anti-[tumor ... five-way clash between rival IL-23p19s, an IL-12/23 juggernaut and at least seven ustekinumab ...

Governors Safeguarding Democracy held January and December briefings on how to handle the National Guard under Trump.

The anti-TNF era was followed by the emergence of ... This therapy, initially thought to owe its efficacy to the inhibition of both IL-12 and IL-23, has since been recognised for its predominant ...